CRISPR/Cas9 PlatformCB is a professional genetic editing biotechnology company that provides transgenic mouse models for biomedical research and drug discovery.

QVirus Platform offers a comprehensive portfolio of oncolytic VACV services for the efficient design, development, manufacturing and analytical testing of virus vector products. So far, we have developed an efficient way to generate recombinant VACVs, including inserting and/or deleting GOI(s) in VACVs. We also provide customized oncolytic vaccinia virus and proof-of-concept validation study for the oncolytic virus.

As a global leader in VLP technology services, Creative Biogene leverages over a decade of technical expertise, international GMP production qualifications, and a comprehensive service system to provide end-to-end solutions for research institutions and pharmaceutical companies—from basic research to industrial production, accelerating the clinical translation and commercialization of innovative therapies.

Creative Biogene, leveraging cutting-edge virology technology platforms, provides pseudovirus construction and customization services covering various viral families. These services support viral function research, vaccine evaluation, neutralizing antibody detection, and antiviral drug screening. Our pseudovirus technology offers a safe and efficient solution for your research and development work.

Creative Biogene specializes in providing high-quality adenovirus vector services, encompassing the construction, amplification, and purification of replication-deficient adenoviruses and helper-dependent adenoviruses (HDAd), supporting various serotypes including Ad5 and Ad5/F35. Leveraging our advanced QVirus platform, we have established mature and stable methodologies for vector construction, in vitro recombination, cellular packaging, recombinant adenovirus amplification, and gradient ultracentrifugation purification, complemented by systematic quality control and identification processe

Miniature editors play a crucial role in genomic editing and gene therapy, particularly in addressing human genetic diseases caused by base mutations. Currently, approximately 60% of known human genetic diseases are attributed to base mutations. Traditional CRISPR technology poses risks such as double-stranded DNA breaks, whereas base editors can efficiently convert single bases at target sites without such breaks.

Cell models play a crucial role in drug screening. Through rapid and precise efficacy assessment and simulation of complex disease environments, they effectively identify potential drug candidates. These models not only aid in understanding drug mechanisms and effects but also support personalized medicine and precision drug development. This advances translational medical research and provides new scientific foundations and treatment strategies for various diseases.

In recent years, CRISPR technology has emerged as a transformative tool in the field of biology. CRISPR library screening is a high-throughput screening method based on the CRISPR/Cas9 gene editing system, designed to interfere with the genome using a large-scale sgRNA library to discover new drug targets associated with specific phenotypes or biological processes. This technology employs precisely designed sgRNA sequences introduced into target cells or organisms, facilitating screening under drug pressure or cell sorting conditions to identify genes closely associated with the target phenoty

GFP Reporter Cell Line-HT1080 is engineered to stably overexpress GFP reporter gene. It is an ideal positive control for use in fluorescence assays. In addition, HT1080 cells form tumors post implantation into immunocompromised mice. The in vivo growth of these tumors can be monitored using optical imaging.